Search the GHTC website

Philip KenolPhilip manages the coalition’s multilateral policy analysis and advocacy work. He develops and implements outreach strategies to the various United Nations agencies and other multilateral organizations to ensure that the coalition is advocating a consistent position with all global health R&D stakeholders.

Philip has a background in global development policy and health care. Before joining GHTC, he served two years as a Senior Dedicated Advisor at the Advisory Board Company, working with hospitals and health care providers on issues surrounding burnout, patient safety, and engagement.

Prior to the Advisory Board, he managed the Alliance for Global Health and Competitiveness, a coalition of private companies and nonprofits that promote strategic investments in health care in developing and middle-income countries. As part of that work, he led lobbying efforts, helped forge new partnerships, and managed high-level roundtables to explore the challenges health decision-makers face.

He started his career at the German Marshall Fund, focusing on economic and development policy, and has worked on several political campaigns, including President Obama’s 2008 run.

Philip received his BA in Government (with a concentration in international development) from Dartmouth College. In his free time, you can usually find Philip playing soccer, rooting for the Capitals, and playing district trivia.

Blog posts written by Philip

Total of 30 blog posts

May 30, 2025

WHO notches much-needed wins at WHA as it faces a crossroads

The 78th World Health Assembly (WHA) was a marathon nine days of decision-making, including the historic adoption of the Pandemic Agreement, the World Health Organization’s (WHO's) attempts to tackle a budget shortfall, and new action plans on antimicrobial resistance and climate and health.

May 28, 2025

Ripple effects: How U.S. FDA layoffs threaten global health in low- and middle-income countries and weaken US competitiveness

As the U.S. Food and Drug Administration (FDA) faces significant staffing reductions, there could be ripple effects for US companies and leadership in the biomedical space, as well as for other countries that depend on the FDA's regulatory leadership to enable access to essential health technologies.

May 14, 2025

PQ Pulse: Advancing regulatory harmonization and accountability in Africa

The World Health Organization’s prequalification (PQ) program plays a critical role in certifying the quality, safety, and efficacy of medical products to expand access to health technologies. In our PQ Pulse interview series, GHTC speaks with stakeholders involved in the PQ process about persistent challenges and potential reforms. Our second interview sheds light on Vizuri Health Dynamics' experience with PQ.

May 8, 2025

The Pandemic Agreement: A much-needed win for multilateralism, R&D, and equity

GHTC breaks down the final draft of the Pandemic Agreement, what it means for research and development (R&D), and the next steps toward its formal adoption and implementation.

March 25, 2025

PQ Pulse: A malaria product developer’s perspective on breaking down silos

The World Health Organization’s prequalification (PQ) program plays a critical role in certifying the quality, safety, and efficacy of medical products to expand access to health technologies. In our PQ Pulse interview series, GHTC speaks with stakeholders involved in the PQ process about persistent challenges and potential reforms. Our first interview sheds light on the Medicines for Malaria Venture's experience with PQ.

February 24, 2025

Is WHO at a turning point?

GHTC reflects on the Recent World Health Organization (WHO) Executive Board meeting in Geneva, Switzerland.